ES2212533T3 - Uso de folistatina para la fabricacion de un medicamento para el tratamiento de trastornos relacionados con los musculos. - Google Patents
Uso de folistatina para la fabricacion de un medicamento para el tratamiento de trastornos relacionados con los musculos.Info
- Publication number
- ES2212533T3 ES2212533T3 ES99908416T ES99908416T ES2212533T3 ES 2212533 T3 ES2212533 T3 ES 2212533T3 ES 99908416 T ES99908416 T ES 99908416T ES 99908416 T ES99908416 T ES 99908416T ES 2212533 T3 ES2212533 T3 ES 2212533T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- folistatin
- dystrophy
- bmp
- gdf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000003205 muscle Anatomy 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 8
- 208000010316 Myotonia congenita Diseases 0.000 claims description 5
- 208000029323 Congenital myotonia Diseases 0.000 claims description 3
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 206010028629 Myoglobinuria Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 3
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 3
- 230000001314 paroxysmal effect Effects 0.000 claims description 3
- 210000001696 pelvic girdle Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 206010052181 Oculopharyngeal dystrophy Diseases 0.000 claims description 2
- 201000011474 congenital myopathy Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 208000035810 Denervation atrophy Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 18
- 230000004069 differentiation Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 6
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 abstract description 4
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 abstract description 4
- 102000001690 Factor VIII Human genes 0.000 abstract description 2
- 108010054218 Factor VIII Proteins 0.000 abstract description 2
- 102000016970 Follistatin Human genes 0.000 abstract 1
- 108010014612 Follistatin Proteins 0.000 abstract 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 38
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 38
- 229940112869 bone morphogenetic protein Drugs 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 21
- 230000027455 binding Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003446 ligand Substances 0.000 description 7
- 102000005606 Activins Human genes 0.000 description 5
- 108010059616 Activins Proteins 0.000 description 5
- 208000029578 Muscle disease Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000000944 nerve tissue Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 206010016208 familial periodic paralysis Diseases 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000931668 Homo sapiens Follistatin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- -1 TGF-? Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37118 | 1998-03-09 | ||
| US09/037,118 US6004937A (en) | 1998-03-09 | 1998-03-09 | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2212533T3 true ES2212533T3 (es) | 2004-07-16 |
Family
ID=21892528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99908416T Expired - Lifetime ES2212533T3 (es) | 1998-03-09 | 1999-02-24 | Uso de folistatina para la fabricacion de un medicamento para el tratamiento de trastornos relacionados con los musculos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6004937A (enExample) |
| EP (3) | EP2347760A3 (enExample) |
| JP (3) | JP2002506044A (enExample) |
| AT (1) | ATE256475T1 (enExample) |
| AU (1) | AU759838B2 (enExample) |
| CA (1) | CA2322716C (enExample) |
| DE (1) | DE69913665T2 (enExample) |
| DK (1) | DK1061940T3 (enExample) |
| ES (1) | ES2212533T3 (enExample) |
| PT (1) | PT1061940E (enExample) |
| WO (1) | WO1999045949A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| ES2255059T3 (es) | 1993-12-07 | 2006-06-16 | Genetics Institute, Llc | Bmp-12, bmp-13 y composiciones suyas inductoras de tendon. |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| WO2001009368A1 (en) * | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| ATE271886T1 (de) | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| EP1790726B1 (en) * | 2001-02-08 | 2013-07-03 | Wyeth LLC | Modified and stabilized GDF propeptides and uses thereof |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| KR100420798B1 (ko) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
| ATE393573T1 (de) | 2001-06-01 | 2008-05-15 | Wyeth Corp | Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US20030103959A1 (en) * | 2001-06-22 | 2003-06-05 | Hughes Paul E. | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| GB2385052A (en) * | 2002-02-05 | 2003-08-13 | Leuven K U Res & Dev | Treatment of spondyloarthropathies |
| WO2003072715A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1: a follistatin domain containing protein |
| AU2003216345A1 (en) * | 2002-02-21 | 2003-09-09 | Wyeth | Follistatin domain containing proteins |
| BR0314270A (pt) * | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US20050192225A1 (en) * | 2002-12-18 | 2005-09-01 | Bowen Richard L. | Methods for treating Parkinson's disease |
| MXPA05012965A (es) * | 2003-06-02 | 2006-03-09 | Wyeth Corp | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. |
| NZ546438A (en) | 2003-09-12 | 2010-07-30 | Wyeth Corp | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| UA93855C2 (ru) * | 2003-12-31 | 2011-03-25 | Шеринг-Плау Лтд. | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CA2575563A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| JP2008526201A (ja) | 2004-12-30 | 2008-07-24 | シェーリング−プラウ・リミテッド | 中和エピトープベースの成長増強ワクチン |
| WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| WO2006107611A2 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| PT2170396T (pt) | 2007-08-03 | 2017-03-31 | Summit Corp Plc | Combinação de fármacos para o tratamento da distrofia muscular de duchenne |
| CA2729096C (en) | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2013313282B2 (en) | 2012-08-01 | 2018-02-01 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| MA51075A (fr) | 2014-06-04 | 2020-10-14 | Acceleron Pharma Inc | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| US9975934B2 (en) | 2015-03-26 | 2018-05-22 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| DE69432815T2 (de) * | 1993-03-19 | 2003-12-11 | The Johns Hopkins University School Of Medicine, Baltimore | Wachstumsfaktor-8 |
| EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
| WO1995010611A1 (en) * | 1993-10-14 | 1995-04-20 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US6281332B1 (en) * | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
-
1998
- 1998-03-09 US US09/037,118 patent/US6004937A/en not_active Expired - Lifetime
-
1999
- 1999-02-24 WO PCT/US1999/004003 patent/WO1999045949A2/en not_active Ceased
- 1999-02-24 AU AU27854/99A patent/AU759838B2/en not_active Ceased
- 1999-02-24 DK DK99908416T patent/DK1061940T3/da active
- 1999-02-24 DE DE69913665T patent/DE69913665T2/de not_active Expired - Lifetime
- 1999-02-24 PT PT99908416T patent/PT1061940E/pt unknown
- 1999-02-24 EP EP10185247A patent/EP2347760A3/en not_active Withdrawn
- 1999-02-24 ES ES99908416T patent/ES2212533T3/es not_active Expired - Lifetime
- 1999-02-24 JP JP2000535362A patent/JP2002506044A/ja not_active Withdrawn
- 1999-02-24 CA CA2322716A patent/CA2322716C/en not_active Expired - Fee Related
- 1999-02-24 EP EP99908416A patent/EP1061940B1/en not_active Expired - Lifetime
- 1999-02-24 EP EP03028901A patent/EP1444985A3/en not_active Withdrawn
- 1999-02-24 AT AT99908416T patent/ATE256475T1/de active
-
2009
- 2009-09-28 JP JP2009222855A patent/JP2010043099A/ja active Pending
-
2010
- 2010-03-17 JP JP2010061242A patent/JP2010195794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1061940A2 (en) | 2000-12-27 |
| AU2785499A (en) | 1999-09-27 |
| ATE256475T1 (de) | 2004-01-15 |
| DE69913665D1 (de) | 2004-01-29 |
| DK1061940T3 (da) | 2004-04-05 |
| EP2347760A3 (en) | 2012-06-06 |
| JP2002506044A (ja) | 2002-02-26 |
| US6004937A (en) | 1999-12-21 |
| AU759838B2 (en) | 2003-05-01 |
| WO1999045949A3 (en) | 1999-11-18 |
| JP2010195794A (ja) | 2010-09-09 |
| WO1999045949A2 (en) | 1999-09-16 |
| DE69913665T2 (de) | 2004-09-30 |
| EP1444985A2 (en) | 2004-08-11 |
| EP2347760A2 (en) | 2011-07-27 |
| CA2322716A1 (en) | 1999-09-16 |
| JP2010043099A (ja) | 2010-02-25 |
| EP1444985A3 (en) | 2006-12-27 |
| EP1061940B1 (en) | 2003-12-17 |
| CA2322716C (en) | 2010-08-24 |
| PT1061940E (pt) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2212533T3 (es) | Uso de folistatina para la fabricacion de un medicamento para el tratamiento de trastornos relacionados con los musculos. | |
| Ladher et al. | Cloning and expression of the Wnt antagonists Sfrp-2 and Frzb during chick development | |
| Nakayama et al. | A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages | |
| ES2479067T3 (es) | Factor de crecimiento neurotrófico | |
| ES2432225T3 (es) | Reactivos y procedimientos para terapias del músculo liso | |
| KR100898765B1 (ko) | 성장인자 복합체 | |
| ES2331441T3 (es) | Dna que codifica dp-75 y un proceso para su uso. | |
| EP1593689A2 (en) | Myostatin and mimetics thereof | |
| ES2246088T3 (es) | Variantes de la proteina 3 de union de factor de crecimiento similar a la insulina. | |
| Anouar et al. | Molecular cloning of frog secretogranin II reveals the occurrence of several highly conserved potential regulatory peptides | |
| US20050053591A1 (en) | Compositions and uses of motor protein-binding moieties | |
| JP2000506373A (ja) | ＴＧＦβシグナル伝達たんぱく質、遺伝子およびその用途 | |
| CN101300269A (zh) | 机械生长因子肽及其用途 | |
| ES2384932T3 (es) | Agente anti-angiogénico y su utilización en el marco del tratamiento de los cánceres | |
| US20200038521A1 (en) | Hyaluronic Acid Binding Domain-Growth Factor Fusion Protein cDNAs and Fusion Proteins for Cartilage Matrix Preservation and Report | |
| JP2004533235A5 (enExample) | ||
| KR102460983B1 (ko) | 새로운 재생 치료제로서의 camkk1 | |
| AU2003231603B2 (en) | Use of follistatin to modulate GDF-8 and BMP-11 | |
| HUT56881A (en) | Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus | |
| HK1159996A (en) | Use of follistatin for the manufacture of a medicament for the treatment of a non-degenerative nervous system disorder | |
| HK1068258A (en) | Use of follistatin for the manufacture of a medicament for the treatment of a non-degenerative nervous system disorder | |
| MXPA00008771A (es) | Uso de folistatina para modular el factor de crecimiento y diferenciacion 8 [gdf-8]y la proteina morfogenetica de hueso 11 [bmp-11] | |
| US12528853B2 (en) | T-cell receptor for treating fibrolamellar hepatocellular carcinoma | |
| Salomon et al. | Oncological aspects of growth factors | |
| CN120518764A (zh) | 使神经元脱髓鞘的重组抗体和应用 |